Distribution in Europe: How Cannabis Companies Actually Reach the Market

Getting a cannabis or cannabinoid product approved for a European market is only the beginning. The harder commercial question is often what happens next: who gets the product to the customer, who controls the relationship, and how much margin remains after everyone in the chain has been paid.

For companies entering Europe, distribution is not simply a logistics decision. It is part of the market-entry strategy.

A product can have strong demand, competitive pricing and a workable regulatory route and still fail commercially because the chosen distribution model does not give the company enough access, margin or control.

Distribution starts with the customer

Before choosing a distributor, define who actually buys the product.

The route to market for a medical cannabis product is fundamentally different from the route for a cosmetic cannabinoid product, a consumer wellness product or another regulated cannabinoid category.

The relevant customer might be a pharmacy wholesaler, clinic, healthcare professional, retail chain, specialist distributor, brand, manufacturer or end consumer.

That distinction determines almost everything that follows.

A company selling into pharmacies may need an established pharmaceutical distribution structure. A consumer brand may be better served by a specialist importer, regional distributor or direct retail strategy. In some markets, a local partner can solve several access problems at once. In others, adding another intermediary simply destroys the economics.

The first distribution question is therefore not: which distributor should we use? It is: what is the shortest compliant route between our product and the customer we need to win?

Distributor or direct sales?

There is no universally correct answer.

A distributor can provide local relationships, sales infrastructure, market knowledge, warehousing and faster access to customers. For a company entering an unfamiliar European market, that can be extremely valuable.

The trade-off is control.

The distributor takes margin. The company may have less visibility into the end customer, less control over pricing and less influence over which products receive attention from the sales team.

Direct sales provide more control over customer relationships, pricing, data and brand positioning. They also require more infrastructure.

That can mean a local sales team, warehousing, customer service, regulatory support, invoicing, collections and potentially a local entity.

For a first market, the additional fixed cost may not be justified.

A useful way to compare the two models is to calculate the real cost of access rather than comparing distributor margin with the cost of hiring a salesperson.

Consider the entire chain:

The number that matters is the margin left after the product reaches the customer.

• Product cost
• Compliance and testing
• Freight
• Import or local handling
• Warehousing
• Distributor or sales cost
• Retailer margin
• Marketing contribution
• Payment and financing costs

The distributor's network matters more than its presentation

A polished website and a long list of brands do not prove distribution capability.

Before signing an agreement, find out what the distributor actually controls.

A distributor may claim national coverage while having strong relationships in only a few regions or channels.

The difference matters.

A company entering Europe does not need a distributor that says it can sell everywhere. It needs a partner that can reach the specific customers that matter for its product.

• Which customers buy from them today?
• Which channels do they cover?
• How many salespeople actively sell the category?
• Which products compete with yours?
• What percentage of their revenue comes from your target category?
• How many units do comparable products actually move?

Distribution concentration changes the negotiation

Some markets have relatively fragmented distribution. Others are controlled by a small number of established players.

The more concentrated the channel, the more important the distributor becomes to the commercial equation.

This can affect:

If two or three companies control most of the relevant channel, the question is not simply whether one of them will distribute the product.

The question is whether the economics of entering through that channel still make sense.

• Wholesale pricing
• Listing terms
• Payment terms
• Promotional requirements
• Minimum order volumes
• Exclusivity
• Launch timing
• Customer data
• Access to key accounts

Margin needs to be modelled backwards

One of the most common mistakes in European market entry is starting with the export price and working forwards.

The better approach is to start with the realistic customer price and work backwards.

Suppose the final customer price appears attractive.

That does not tell you whether the manufacturer has a viable business.

The calculation needs to account for every margin and cost between the factory and the customer.

For a consumer product, that might include importer margin, distributor margin, retailer margin, VAT, logistics, testing, warehousing, promotional activity and payment terms.

For medical products, the structure can be significantly more complex because the applicable regulatory and pharmaceutical distribution requirements vary by market.

For medicinal products, wholesale distribution in the EEA is subject to national authorisation requirements and Good Distribution Practice requirements. The European Medicines Agency notes that wholesale distributors must hold a wholesale distribution authorisation issued by the relevant national competent authority.

That is why "we have a distributor in Europe" is not enough information.

The relevant question is whether that distributor is authorised and operationally capable of handling the specific product category in the target market.

Regulatory status and distribution are connected

Distribution cannot be separated from regulation.

The product category determines who can sell it, where it can be stored, what documentation is required and which parties can legally handle it.

This is particularly important for companies dealing with medical cannabis and other regulated products.

For medicinal products, European GDP rules cover areas including sourcing, storage, transportation, traceability and recall procedures. National authorities are responsible for wholesale distribution authorisations in their respective jurisdictions.

Other cannabinoid products may fall under completely different regulatory frameworks.

That means a distributor experienced with one cannabis category may be completely unsuitable for another.

Do not evaluate distribution capability separately from regulatory capability.

Exclusivity is expensive

European distributors often ask for exclusivity.

Sometimes that is justified.

A distributor investing in registration, market development, sales staff and customer relationships may reasonably want protection from being undercut by another partner.

But exclusivity also transfers leverage away from the manufacturer.

Before granting it, define exactly what the distributor is expected to deliver.

Exclusivity should be earned through performance, not granted simply because a distributor asks for it.

A company can lose an entire market for years by giving exclusive rights to a partner that does not actually develop the business.

• Minimum annual volumes.
• Number of active accounts.
• Launch milestones.
• Marketing commitments.
• Reporting requirements.
• Payment performance.
• Termination rights.
• Territory.
• Product scope.
• Duration.

Due diligence should go beyond references

References are useful, but they are not enough.

Ask for evidence.

Look at the distributor's current portfolio. Speak with customers where possible. Understand which brands receive attention from the sales team. Check whether competing products are already represented.

For regulated products, verify the relevant authorisations and compliance capabilities.

For medicinal products, the EudraGMDP database provides public information on wholesale distribution authorisations and registered activities in the EEA.

Also examine the financial side.

A distributor that takes 60 or 90 days to pay can effectively become a financing requirement for the manufacturer.

That matters even more when the company is funding inventory, compliance work and market-entry costs at the same time.

Direct sales can make sense earlier than expected

Using a distributor is not automatically cheaper.

If the distributor requires a large margin but generates limited sales, the manufacturer may be paying heavily for access without receiving meaningful scale.

Direct sales can make sense when:

A hybrid model can also work.

A company may manage key accounts directly while using a distributor for smaller customers, logistics or regional coverage.

The right model can also change over time.

A distributor may be the best way to enter a market and the wrong way to scale it.

• The target customer base is concentrated
• The product has a high enough margin
• The company needs direct customer data
• The market is strategically important
• The sales cycle is manageable
• The regulatory structure allows the company to operate directly

Distribution should follow market selection

Distribution decisions are much easier once the target markets have been compared properly.

A market with strong theoretical demand may become unattractive if access is controlled by a small number of distributors with demanding commercial terms.

A smaller market may become attractive if the company can enter quickly, establish reference customers and build a repeatable route to market.

This is why distribution should be included in the market-selection process rather than treated as a separate operational decision.

For each candidate market, assess:

The result should be a distribution model that supports the market-entry strategy rather than dictating it.

• Number and quality of relevant distributors
• Channel concentration
• Expected distributor margin
• Minimum order requirements
• Payment terms
• Local warehousing requirements
• Regulatory responsibilities
• Exclusivity expectations
• Speed to first sale
• Ability to reach key customers directly

What a strong European distribution strategy looks like

There is no single European distribution model.

A strong strategy is usually built market by market.

Start with the product. Define the regulatory route. Identify the customer. Map the channel. Calculate the economics. Identify the companies that actually control access.

Then decide whether the best route is a distributor, direct sales, a local entity or a combination.

The important part is the order of decisions.

Choosing a distributor first and then trying to build the market around that relationship is backwards.

Choose the market and commercial model first. Then select the distribution partner that fits it.

What to do next

If you are evaluating several European markets, distribution should be one of the criteria in the initial market comparison rather than a decision made after the country has already been selected.

Compare at least three markets using the same assumptions.

Look at access, margins, channel concentration, regulatory requirements and time to first sale.

Then test the assumptions with actual distributors and customers before committing significant capital.

That process gives you something more useful than a list of potential distributors.

It gives you a market-entry strategy.

At Canna Euro Consulting, we help companies assess European markets, distribution structures and market-entry options before they commit capital. Our cannabis market entry calculator provides a structured first assessment, while our consulting services can take the analysis further into market selection, distribution and implementation.

For the broader market-selection framework, see our guide to choosing the right European cannabis market.